105 related articles for article (PubMed ID: 31032491)
1. Decreased pyruvate dehydrogenase activity in Tafazzin-deficient cells is caused by dysregulation of pyruvate dehydrogenase phosphatase 1 (PDP1).
Liang Z; Ralph-Epps T; Schmidtke MW; Kumar V; Greenberg ML
J Biol Chem; 2024 Mar; 300(3):105697. PubMed ID: 38301889
[TBL] [Abstract][Full Text] [Related]
2. Barth syndrome.
Jefferies JL
Am J Med Genet C Semin Med Genet; 2013 Aug; 163C(3):198-205. PubMed ID: 23843353
[TBL] [Abstract][Full Text] [Related]
3. Increased mtDNA Abundance and Improved Function in Human Barth Syndrome Patient Fibroblasts Following AAV-
Suzuki-Hatano S; Sriramvenugopal M; Ramanathan M; Soustek M; Byrne BJ; Cade WT; Kang PB; Pacak CA
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31336787
[TBL] [Abstract][Full Text] [Related]
4. Stem cell models of TAFAZZIN deficiency reveal novel tissue-specific pathologies in Barth Syndrome.
Sniezek Carney O; Harris KW; Wohlfarter Y; Lee K; Butschek G; Anzmann A; Claypool SM; Hamacher-Brady A; Keller M; Vernon HJ
bioRxiv; 2024 Apr; ():. PubMed ID: 38746168
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of cardiolipin nanodisks as lipid replacement therapy for Barth syndrome.
Ikon N; Hsu FF; Shearer J; Forte TM; Ryan RO
J Biomed Res; 2018 Mar; 32(2):107-112. PubMed ID: 29336355
[TBL] [Abstract][Full Text] [Related]
6. Anomalous peroxidase activity of cytochrome c is the primary pathogenic target in Barth syndrome.
Kagan VE; Tyurina YY; Mikulska-Ruminska K; Damschroder D; Vieira Neto E; Lasorsa A; Kapralov AA; Tyurin VA; Amoscato AA; Samovich SN; Souryavong AB; Dar HH; Ramim A; Liang Z; Lazcano P; Ji J; Schmidtke MW; Kiselyov K; Korkmaz A; Vladimirov GK; Artyukhova MA; Rampratap P; Cole LK; Niyatie A; Baker EK; Peterson J; Hatch GM; Atkinson J; Vockley J; Kühn B; Wessells R; van der Wel PCA; Bahar I; Bayir H; Greenberg ML
Nat Metab; 2023 Dec; 5(12):2184-2205. PubMed ID: 37996701
[TBL] [Abstract][Full Text] [Related]
7. Temporal evolution of the heart failure phenotype in Barth syndrome and treatment with elamipretide.
Sabbah HN; Taylor C; Vernon HJ
Future Cardiol; 2023 Mar; 19(4):211-225. PubMed ID: 37325898
[TBL] [Abstract][Full Text] [Related]
8. Cardiolipin metabolism regulates expression of muscle transcription factor MyoD1 and muscle development.
Vo L; Schmidtke MW; Da Rosa-Junior NT; Ren M; Schlame M; Greenberg ML
J Biol Chem; 2023 Mar; 299(3):102978. PubMed ID: 36739949
[TBL] [Abstract][Full Text] [Related]
9. Higher IL-6 and IL6:IGF Ratio in Patients with Barth Syndrome.
Wilson LD; Al-Majid S; Rakovski CS; Schwindt CD
J Inflamm (Lond); 2012 Jun; 9(1):25. PubMed ID: 22721508
[TBL] [Abstract][Full Text] [Related]
10. Perturbations in mitochondrial metabolism associated with defective cardiolipin biosynthesis: An
Rua AJ; Mitchell W; Claypool SM; Alder NN; Alexandrescu AT
bioRxiv; 2024 Jun; ():. PubMed ID: 38948727
[TBL] [Abstract][Full Text] [Related]
11. "I Want That Life a Lot…How on Earth Do I Get That?" Examining Challenges for Men With Barth Syndrome in Their Transitions to Adulthood.
Mazar I; Moorman SM
J Patient Exp; 2021; 8():23743735211060783. PubMed ID: 34869844
[TBL] [Abstract][Full Text] [Related]
12. The Story of Ammonia in Liver Disease: An Unraveling Continuum.
Anand AC; Acharya SK
J Clin Exp Hepatol; 2024; 14(4):101361. PubMed ID: 38444405
[TBL] [Abstract][Full Text] [Related]
13. Barth Syndrome Cardiomyopathy: An Update.
Pang J; Bao Y; Mitchell-Silbaugh K; Veevers J; Fang X
Genes (Basel); 2022 Apr; 13(4):. PubMed ID: 35456462
[TBL] [Abstract][Full Text] [Related]
14. Studying Lipid-Related Pathophysiology Using the Yeast Model.
Ralph-Epps T; Onu CJ; Vo L; Schmidtke MW; Le A; Greenberg ML
Front Physiol; 2021; 12():768411. PubMed ID: 34777024
[No Abstract] [Full Text] [Related]
15. Barth Syndrome: Exploring Cardiac Metabolism with Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Fatica EM; DeLeonibus GA; House A; Kodger JV; Pearce RW; Shah RR; Levi L; Sandlers Y
Metabolites; 2019 Dec; 9(12):. PubMed ID: 31861102
[TBL] [Abstract][Full Text] [Related]
16. Barth syndrome: mechanisms and management.
Finsterer J
Appl Clin Genet; 2019; 12():95-106. PubMed ID: 31239752
[No Abstract] [Full Text] [Related]
17. Barth syndrome: A life-threatening disorder caused by abnormal cardiolipin remodeling.
Raja V; Reynolds CA; Greenberg ML
J Rare Dis Res Treat; 2017; 2(2):58-62. PubMed ID: 31032491
[TBL] [Abstract][Full Text] [Related]
18. Barth syndrome cardiomyopathy: targeting the mitochondria with elamipretide.
Sabbah HN
Heart Fail Rev; 2021 Mar; 26(2):237-253. PubMed ID: 33001359
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
